• Call: 7506942069
  • Mumbai, India
  • Mon - Fri: 9.00am - 04.00pm

What's The BEST Approach To Pancreatic Cancer Management in 2025?

In this video, Dr. Gunjan Desai, a pancreatic surgeon in Mumbai, at Lilavati Hospital, provides an in-depth discussion on managing resectable and borderline resectable pancreatic cancer. Pancreatic cancer remains one of the most challenging malignancies, with surgical resection being the only potentially curative option. However, determining the best treatment strategy requires a multidisciplinary approach integrating surgery, chemotherapy, and sometimes radiation therapy to optimize outcomes.

Dr. Desai begins by defining resectable pancreatic cancer, which is characterized by the absence of vascular invasion, making it suitable for upfront surgery. In contrast, borderline resectable pancreatic cancer involves limited vascular involvement, requiring a more strategic approach, often incorporating neoadjuvant therapy to improve resectability and survival rates.

A key focus of the discussion is the role of neoadjuvant therapy and how it impacts treatment outcomes. Dr. Desai highlights major clinical trials that have shaped current treatment protocols, including the NORPACT 1 trial and the ESPAC 5 trial. The NORPACT 1 trial evaluated the efficacy of neoadjuvant FOLFIRINOX chemotherapy in patients with resectable pancreatic cancer, investigating whether a preoperative approach could enhance survival compared to immediate surgery. Findings from this study provide important insights into the potential benefits of systemic disease control before resection.

Additionally, the ESPAC 5 trial is explored, which examined various neoadjuvant and adjuvant therapy strategies for both resectable and borderline resectable pancreatic cancer. This study assessed different chemotherapy regimens to determine the most effective treatment combinations for improving overall survival. Dr. Desai discusses how ESPAC 5 findings are shaping clinical decision-making, particularly in tailoring treatment based on tumor biology and response to systemic therapy.

In the latter part of the discussion, Dr. Desai reviews the latest ESMO 2023 guidelines for the management of resectable and borderline resectable pancreatic cancer. These updated guidelines emphasize a personalized approach based on patient performance status, tumor characteristics, and response to treatment. For resectable pancreatic cancer, ESMO 2023 strongly supports neoadjuvant therapy in select patients, particularly those with high-risk features, as it may improve surgical outcomes and long-term survival. The guidelines also recommend FOLFIRINOX-based chemotherapy as the preferred adjuvant treatment due to its superior survival benefit compared to gemcitabine-based regimens.

For borderline resectable pancreatic cancer, the ESMO 2023 guidelines endorse neoadjuvant therapy as the standard of care, recognizing its ability to increase the likelihood of achieving an R0 resection. The guidelines highlight the role of FOLFIRINOX or gemcitabine/nab-paclitaxel regimens, depending on patient tolerance and comorbidities. Dr. Desai also discusses the evolving role of radiation therapy, particularly stereotactic body radiotherapy (SBRT) in select cases where tumor shrinkage is required before surgery.

Throughout the video, Dr. Desai underscores the importance of a multidisciplinary team in managing pancreatic cancer, including oncologists, radiologists, and gastroenterologists. He also explores emerging treatment strategies, including genomic profiling and targeted therapies, that may further enhance patient outcomes.

This comprehensive discussion provides valuable insights for oncologists, surgeons, medical professionals, and patients seeking to understand the latest advancements in pancreatic cancer management. Be sure to watch till the end for expert recommendations and key takeaways on optimizing treatment strategies for this aggressive disease.




FACEBOOK: https://bit.ly/3qaO53R

TWITTER: https://bit.ly/3legZw7

INSTAGRAM: https://bit.ly/33mAJaK

E-MAIL ID: learnwithedusurg@gmail.com

WE SUPPORT AND RECOMMEND

Freedom of expression, positivity, and meditation

VISIT THE LINK, IF YOU DO TOO.

OUR MOST VIEWED SURGERY VIDEOS

STEP BY STEP LAPAROSCOPIC CHOLECYSTECTOMY

CRITICAL VIEW OF SAFETY IN LAP CHOLECYSTECTOMY